Access widened to funded medicines

Last updated 05:00 13/11/2012

Relevant offers

Health

Respiratory conditions to blame for one in 10 overnight hospitalisations Ministry of Health says relief is coming for packed mental health crisis beds Neck strength could influence impact of concussions, Dunedin study finds Palmerston North Hospital says changes not a sign of future cost-cutting Malaghan ties the knot with China for cancer vaccine trials St John Marlborough rallies to meet daily $1000 shortfall It's been banned in many of the world's major cities, but a controversial anti-vaccine movie will screen in Auckland Young Tokoroa leukemia sufferer pushes on Paramedic shortage hits Taupo, says union No smokes without fire: Philip Morris' 'Heat not burn' tobacco sales under scrutiny

Pharmac has spent more than $21.5 million on new drugs and widening access to publicly funded medicines in the past year.

Blood thinning drug Pradaxa, also known as dabigatran, was the most expensive new drug to be funded, with an estimated annual cost of $16 million.

Two new drugs targeting specific types of breast and kidney cancer were also added to the list of funded medications.

More people can access the drug rituximab, which is used to treat some kinds of lymphomas. Breast cancer drug docetaxel has also been made more widely available and access to funded treatment for Crohn's disease, Cystic fibrosis and asthma were widened.

The Government's drug-buying agency yesterday released its annual report for the year ending June 30, which showed 14 new medicines were funded in the past year and access to 10 others was widened.

An extra 56,840 patients were expected to benefit from the changes, on top of the record 3.3 million New Zealanders who received fully funded medication in the past year.

Pharmac stayed within its $777.4m budget in a year which saw it take on additional roles, including managing the national immunisation schedule and hospital medicines and medical devices.

It also contributed $379,000 towards a research trial in Finland looking at whether the nine week or 12-month duration of breast cancer drug Herceptin offers a better treatment.

Ad Feedback

- The Dominion Post

Special offers
Opinion poll

Should fluoride in water be the responsibility of central government?

Yes

No

Vote Result

Featured Promotions

Sponsored Content